Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...

Some dosage strengths of both Victoza and Saxenda are included on the FDA's shortages list, mainly due to pressures on Novo Nordisk's production capacity for its entire GLP-1 franchise ...

Kendrick Lamar has taken the lead for his first UK Number 1 single. Not Like Us charges up to Number 1 midweek, following its Top 10 re-entry last week, following Kendrick’s acclaimed Super Bowl ...

Objectives were to provide dose-increment justification for conversion of a patient from ... the two regimens were equivalent (AUC ratio ~1.0). Divalproex ER administered once daily had less ...

“Most people have understood Ozempic as kind of a catch-all for the GLP-1 class of medications ... Another difference between the two is the dosage, she notes. Wegovy doses go up higher ...